Alder BioPharmaceuticals (Alder BioPharmaceuticals) Debt-to-Equity : 0.89 (As of Jun. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals Debt-to-Equity?

Alder BioPharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2019 was $0.98 Mil. Alder BioPharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2019 was $192.38 Mil. Alder BioPharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2019 was $216.85 Mil. Alder BioPharmaceuticals's debt to equity for the quarter that ended in Jun. 2019 was 0.89.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alder BioPharmaceuticals's Debt-to-Equity or its related term are showing as below:

ALDR's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Alder BioPharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Alder BioPharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals Debt-to-Equity Chart

Alder BioPharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Debt-to-Equity

Get a 7-Day Free Trial

0.85

Alder BioPharmaceuticals Quarterly Data
	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19
Debt-to-Equity	Get a 7-Day Free Trial															0.52	0.63	0.85	0.73	0.89

Competitive Comparison of Alder BioPharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Alder BioPharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alder BioPharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alder BioPharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alder BioPharmaceuticals's Debt-to-Equity falls into.

Alder BioPharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alder BioPharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	182.104)	/	213.731
	=	0.85

Alder BioPharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.981	+	192.384)	/	216.851
	=	0.89

Alder BioPharmaceuticals (NAS:ALDR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alder BioPharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11804 North Creek Parkway South, Bothell, WA, USA, 98011

Website

http://www.alderbio.com

Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.

Executives

Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S	10 percent owner	9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno	director
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby	director, officer: President and CEO	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston	director	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green	director	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	director	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton	officer: Chief Business Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter	officer: Interim Chief Medical Officer	C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620